Loading articles...

Quebec-based Medicago reports promising early Phase 1 results of possible COVID-19 vaccine

Last Updated Nov 10, 2020 at 12:44 pm EST

File photo of a disposable plastic medical syringe with attached hypodermic needle. GI PHOTO STOCK.
Summary

Interim results of a Phase 1 clinical trial found 100% of subjects developed a promising antibody response after 2 doses


Medicago says the side effects were generally mild to moderate and short in duration


It plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval


Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19.

The Quebec City-based company says interim results of a Phase 1 clinical trial found that 100 per cent of subjects developed a promising antibody response after two doses of its COVID-19 vaccine candidate.

Medicago says the side effects were generally mild to moderate and short in duration.

The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people.

Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.

The federal government has signed deal with Medicago to secure the rights to buy 76 million doses of its vaccine. Medicago will also receive $173 million in funding from Ottawa for its vaccine research and development and for the construction of its Quebec City manufacturing facility.